ZetrOZ Systems, the creators of sustained acoustic medicine and the manufacturers of the revolutionary sam® wearable ultrasound unit, concluded the first half of 2024 with presentations at three major medical conferences. At these events, the company shared the latest research on the effectiveness of its technology in enhancing platelet-rich plasma treatments for soft tissue healing.
In May, ZetrOZ Systems participated in the annual meetings of the Special Operations Medical Association (SOMA), the College Athletics Trainers Association (CATS), and the National Basketball Association Trainers Association (NBATA). During these events, NBATA honored ZetrOZ Systems with a Silver Partnership award.
All three groups are significant stakeholders for ZetrOZ Systems. The sam® line of devices is widely utilized in recreational, college, and professional sports to expedite the return of injured athletes to practices and games. Moreover, these devices are covered by most college and private insurance plans.
The sam® device family is also included under federal contracts for many U.S. military and veteran patients, offering a viable and cost-effective option for government personnel who sustain injuries in the line of duty.
“As we reach the midpoint of the year, I’m extremely pleased that we have been able to meet with so many physicians and medical professionals and bring them the evidence that sam® truly speeds injury healing and can help people get back quickly to doing the things that matter to them,” said George Lewis, founder and CEO of ZetrOZ Systems. “This recent soft tissue healing study demonstrates that sustained acoustic medicine can effectively treat soft tissue injury without the need for invasive procedures.”
During a conference, ZetrOZ Systems presented research that was published in the journal Orthopedic & Muscular System: Current Research in August 2023. The study examined the recovery of 35 elite college athletes, mostly football players, who had sustained leg, knee, or wrist tendon injuries during the 2022-2023 season.
The group was split in half, with one receiving platelet-rich plasma (PRP) injections, and the other receiving both PRP and long-duration ultrasound (LDU) treatment with ZetrOZ Systems’ sam® 2.0 device for four hours a day for 14 days.
The results showed that athletes who received the combined PRP and LDU treatment returned to play 21.33 days faster than those receiving the PRP treatment alone. Additionally, those receiving both treatments reported less pain and better overall health. Furthermore, examinations six months later found that the treatment had no adverse effects on healing.
“The combination of PRP + LDU therapy provides a significant reduction in time to return to sport without impacting the long-term durability of the soft tissue. It increases pain reduction and overall health improvement for patients recovering from a sport-related injury,” the study’s authors concluded. “Non-invasive LDU therapy provides a valuable tool to expedite tissue regeneration and should be considered by practitioners to augment regenerative medicine approaches such as PRP.”
The August 2023 study is one of over 40 peer-reviewed publications, which include 20 Level 1-5 clinical studies. These studies have found sustained acoustic medicine to be effective in treating knee osteoarthritis and a range of soft tissue injuries.
ZetrOZ Systems’ sustained acoustic medicine mechanobiological technology works by increasing blood vessel diameters to improve blood flow, increasing oxygenated hemoglobin at the site, and removing cytokine enzymes and cellular waste for rapid healing and reduced pain.
The sam® devices are the only FDA-cleared, long-duration ultrasound devices for prescription home use. They have successfully treated hundreds of thousands of patients.
